AI Assistant
Blog
Pricing
Log In
Sign Up
Mersana Therapeutics, Inc. Initiates Phase I Trial of Anti-Cancer Agent, XMT-1001, in Solid Tumors
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
